12:00 AM
Sep 10, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

TC-5214: Phase IIb start

Next half, Targacept will begin a Phase IIb trial of TC-5214. In March, Targacept and former partner AstraZeneca plc (LSE:AZN; NYSE:AZN, London, U.K.) abandoned plans to submit regulatory...

Read the full 130 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >